<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3087179/" ref="ordinalpos=392&amp;ncbi_uid=3381968&amp;link_uid=PMC3087179" image-link="/pmc/articles/PMC3087179/figure/F5/" class="imagepopup">Figure 5. The model of IL-4R <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> in RMS.  From: IL-4R Drives Dedifferentiation, Mitogenesis and Metastasis in Rhabdomyosarcoma. </a></div><br /><div class="p4l_captionBody">In embryonal rhabdomyosarcoma (ERMS), IL-4R signaling pathway is mediated by the type II IL-4R complex (IL-4Rα/IL-13Rα1). Both IL-4 and IL-13 stimulate the type II heterodimeric receptor, then intracellular STAT6 protein is phosphorylated to induce tumor progression. In alveolar rhabdomyosarcoma (ARMS), both the type I (IL-4Rα/common γ chain) and type II receptor complex are highly expressed. IL-4 and/or IL-13 activate IL-4R signaling pathway in ARMS mediated by these receptor complexes, resulting in tumor progression including lymph node and pulmonary metastasis.</div></div>